Refining Vancomycin Use in Early CDI
A modified dosing approach could reshape recurrence prevention strategies.
By
Julia Cipriano, MS, CMPP
March 4, 2026
Clinical Scorecard: Refining Vancomycin Use in Early CDI
At a Glance
Category Detail
Condition Clostridioides difficile infection (CDI) Key Mechanisms Vancomycin pulse-and-taper regimen vs. standard pulse therapy Target Population Adult patients with first episode or first recurrence of CDI Care Setting Hospital-based treatment
Key Highlights
74% probability of superiority of 4-week vancomycin pulse-and-taper regimen over 2-week pulse regimen Recurrence rates at day 56: 15% (taper) vs 18% (placebo) Adverse effects were uncommon in both treatment groups Study conducted across 12 Canadian hospitals Need for further pragmatic randomized evidence emphasized Guideline-Based Recommendations
Diagnosis
Laboratory-confirmed CDI with clinical improvement by day 10 of treatment Management
Consider 4-week vancomycin pulse-and-taper regimen for preventing recurrence Monitoring & Follow-up
Monitor recurrence rates at day 38 and day 56 post-treatment Risks
Potential for delayed recurrences despite treatment Patient & Prescribing Data
265 adult patients with CDI
Vancomycin (125 mg four times daily) followed by taper regimen showed lower recurrence rates
Clinical Best Practices
Utilize pulse-and-taper regimen for patients with CDI to reduce recurrence risk Monitor patients closely for signs of recurrence post-treatment Related Resources & Content
